Cullinan 制药

最新新闻

• 评级变动
  Morgan Stanley Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/9/26
• 评级变动
  Clear Street Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $47
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Analysts Offer Insights on Healthcare Companies: BrightSpring Health Services, Inc. (BTSG) and Cullinan Management (CGEM)
  TipRanks · 2026/10/2
• 评级变动
  BTIG Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  Clear Street Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $47
  \u5e02\u573a\u8d44\u8baf · 2026/8/15
• Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Citi Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  BTIG Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $39
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $37
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $33 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• BTIG Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• William Blair Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  UBS Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $27
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $42
  \u5e02\u573a\u8d44\u8baf · 2026/9/15

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。